<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Iron chelators for acute stroke - Van der Loo, LE - 2020 | Cochrane Library</title> <meta content="Iron chelators for acute stroke - Van der Loo, LE - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009280.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Iron chelators for acute stroke - Van der Loo, LE - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009280.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009280.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Iron chelators for acute stroke" name="citation_title"/> <meta content="Lars E Van der Loo" name="citation_author"/> <meta content="Maastricht University Medical Centre" name="citation_author_institution"/> <meta content="René Aquarius" name="citation_author"/> <meta content="Radboud University Medical Center" name="citation_author_institution"/> <meta content="Onno Teernstra" name="citation_author"/> <meta content="Maastricht University Medical Centre" name="citation_author_institution"/> <meta content="Catharina JM Klijn" name="citation_author"/> <meta content="Radboud University Medical Center" name="citation_author_institution"/> <meta content="Tomas Menovsky" name="citation_author"/> <meta content="Antwerp University Hospital" name="citation_author_institution"/> <meta content="J Marc C van Dijk" name="citation_author"/> <meta content="University Medical Center Groningen" name="citation_author_institution"/> <meta content="Ronald Bartels" name="citation_author"/> <meta content="Radboud University Medical Center" name="citation_author_institution"/> <meta content="Hieronymus Damianus Boogaarts" name="citation_author"/> <meta content="Radboud University Medical Centre" name="citation_author_institution"/> <meta content="jeroen.boogaarts@radboudumc.nl" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD009280.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/11/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009280.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009280.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009280.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Bias; Deferoxamine [adverse effects, *therapeutic use]; Hemorrhagic Stroke [*drug therapy, mortality]; Iron Chelating Agents [adverse effects, *therapeutic use]; Neuroprotective Agents [adverse effects, *therapeutic use]; Placebos [therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009280.pub3&amp;doi=10.1002/14651858.CD009280.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="na56WA6j";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009280\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009280\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","pt","ko","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009280.pub3",title:"Iron chelators for acute stroke",firstPublishedDate:"Nov 25, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=na56WA6j&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009280.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009280.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009280.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009280.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009280.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009280.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009280.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009280.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009280.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009280.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2245 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009280.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/full#CD009280-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/full#CD009280-sec-0064"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/full#CD009280-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/full#CD009280-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/full#CD009280-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/full#CD009280-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/full#CD009280-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/full#CD009280-sec-0058"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/appendices#CD009280-sec-0068"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Iron chelators for acute stroke</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/information#CD009280-cr-0004">Lars E Van der Loo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/information#CD009280-cr-0005">René Aquarius</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/information#CD009280-cr-0006">Onno Teernstra</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/information#CD009280-cr-0007">Catharina JM Klijn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/information#CD009280-cr-0008">Tomas Menovsky</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/information#CD009280-cr-0009">J Marc C van Dijk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/information#CD009280-cr-0010">Ronald Bartels</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009280.pub3/information#CD009280-cr-0011"><i class="icon corresponding-author fa fa-envelope"></i>Hieronymus Damianus Boogaarts</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/information/en#CD009280-sec-0078">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 November 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009280.pub3">https://doi.org/10.1002/14651858.CD009280.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009280-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009280-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009280-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009280-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009280-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009280-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD009280-abs-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009280-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009280-abs-0001" lang="en"> <section id="CD009280-sec-0001"> <h3 class="title" id="CD009280-sec-0001">Background</h3> <p>Stroke is the second leading cause of death and a major cause of morbidity worldwide. Retrospective clinical and animal studies have demonstrated neuroprotective effects of iron chelators in people with haemorrhagic or ischaemic stroke. This is the first update of the original Cochrane Review published in 2012. </p> </section> <section id="CD009280-sec-0002"> <h3 class="title" id="CD009280-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of iron‐chelating drugs in people with acute stroke. </p> </section> <section id="CD009280-sec-0003"> <h3 class="title" id="CD009280-sec-0003">Search methods</h3> <p>We searched the Cochrane Stroke Group Trials Register (2 September 2019), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2019, Issue 9; 2 September 2019), MEDLINE Ovid (2 September 2019), Embase Ovid (2 September 2019), and Science Citation Index (2 September 2019). We also searched ongoing trials registers. </p> </section> <section id="CD009280-sec-0004"> <h3 class="title" id="CD009280-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of iron chelators versus no iron chelators or placebo for the treatment of acute stroke, including subarachnoid haemorrhage. </p> </section> <section id="CD009280-sec-0005"> <h3 class="title" id="CD009280-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the search results. We obtained the full texts of potentially relevant studies and evaluated them for eligibility. We assessed risk of bias using the Cochrane 'Risk of bias' tool, and the certainty of evidence using the GRADE approach. </p> </section> <section id="CD009280-sec-0006"> <h3 class="title" id="CD009280-sec-0006">Main results</h3> <p>Two RCTs (333 participants) were eligible for inclusion; both compared the iron‐chelating agent deferoxamine against placebo. Both studies evaluated participants with spontaneous intracerebral haemorrhage. We assessed one study to have a low risk of bias; the other study had potential sources of bias. </p> <p>The limited and heterogeneous data did not allow for meta‐analysis of the outcome parameters. The evidence suggests that administration of deferoxamine may result in little to no difference in deaths (8% in placebo vs 8% in deferoxamine at 180 days; 1 RCT, 291 participants; low‐certainty evidence). These RCTs suggest that there may be little to no difference in good functional outcome (modified Rankin Scale score 0 to 2) between groups at 30, 90 and 180 days (placebo vs deferoxamine: 67% vs 57% at 30 days and 36% vs 45% at 180 days; 2 RCTs, 333 participants; low‐certainty evidence). One RCT suggests that administration of deferoxamine may not increase the number of serious adverse events or deaths (placebo vs deferoxamine: 33% vs 27% at 180 days; risk ratio 0.81, 95 % confidence interval 0.57 to 1.16; 1 RCT, 291 participants; low‐certainty evidence). No data were available on any deaths within the treatment period. Deferoxamine may result in little to no difference in the evolution of National Institute of Health Stroke Scale scores from baseline to 90 days (placebo vs deferoxamine: 13 to 4 vs 13 to 3; P = 0.37; 2 RCTs, 333 participants; low‐certainty evidence). Deferoxamine may slightly reduce relative oedema surrounding intracerebral haemorrhage at 15 days (placebo vs deferoxamine: 1.91 vs 10.26; P = 0.042; 2 RCTs, 333 participants; low‐certainty evidence). Neither study reported quality of life. </p> </section> <section id="CD009280-sec-0007"> <h3 class="title" id="CD009280-sec-0007">Authors' conclusions</h3> <p>We identified two eligible RCTs for assessment. We could not demonstrate any benefit for the use of iron chelators in spontaneous intracerebral haemorrhage. The added value of iron‐chelating therapy in people with ischaemic stroke or subarachnoid haemorrhage remains unknown. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009280-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009280-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009280-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009280-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009280-abs-0018">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009280-abs-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD009280-abs-0013">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009280-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009280-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD009280-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009280-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD009280-abs-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009280-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009280-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009280-abs-0002" lang="en"> <h3>Drugs for reducing iron in people with acute stroke</h3> <p><b>Background</b> </p> <p>Brain damage after stroke is complex, and consists of both direct and delayed damage. A disturbance in local iron levels may be linked to delayed brain damage. Therefore, limiting iron toxicity is a potential target in the treatment of people with stroke. Iron‐chelating drugs are able to bind excess iron in blood and in local tissue, and may reduce iron accumulation and iron‐related brain injury. In animal studies, iron‐chelating drugs have been shown to protect brain cells after occurrence of stroke. </p> <p><b>Search date</b> </p> <p>The updated search was performed on 2 September 2019.</p> <p><b>Study characteristics</b> </p> <p>We identified two trials, with 333 participants in total, which investigated the effectiveness on good clinical outcome of iron chelation therapy with deferoxamine for acute stroke. Both trials studied the effect in people who had bleeding in the brain, a subset of acute stroke. </p> <p><b>Key results</b> </p> <p>With the limitation that studies could not be pooled, the data did not show any difference in good neurological outcome between groups. Both studies reported that administration of deferoxamine was safe. Oedema formation around the haematoma was slightly reduced in the deferoxamine group in one study, but not in the other. </p> <p><b>Certainty of the evidence</b> </p> <p>The certainty of the evidence for the use of deferoxamine for the improvement of neurological outcome in spontaneous intracerebral haemorrhage is low. This is based on two small studies with short follow‐up, and with differences in outcome measurement. Limited evidence was available regarding side effects. The added value of iron‐chelating therapy in people with ischaemic stroke or subarachnoid haemorrhage remains unknown. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009280-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009280-sec-0064"></div> <h3 class="title" id="CD009280-sec-0065">Implications for practice</h3> <section id="CD009280-sec-0065"> <p>There is limited evidence for the administration of iron chelators in acute stroke. We could not demonstrate any benefit for the use of iron chelators in spontaneous intracranial haemorrhage (ICH) with regards to good clinical outcome. The added value of iron‐chelating therapy in people with ischaemic stroke or subarachnoid haemorrhage remains unknown. </p> </section> <h3 class="title" id="CD009280-sec-0066">Implications for research</h3> <section id="CD009280-sec-0066"> <p>There are only two completed randomised controlled trials (RCTs) that compare the effect of any iron chelator with placebo or no intervention in people with ICH. <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> indicated that, while treatment with deferoxamine was safe, any effects of iron chelators would be modest and would require a large RCT to exclude such a modest effect. The value of such a trial is uncertain. </p> <p>The design and performance of future research should ensure:</p> <p> <ul id="CD009280-list-0011"> <li> <p>appropriate methods of randomisation with adequate concealment of allocation;</p> </li> <li> <p>double‐blinding (blinding investigators, participants and outcome assessors);</p> </li> <li> <p>standard dichotomous functional outcome measurement;</p> </li> <li> <p>evaluation of therapeutic effect and adverse events;</p> </li> <li> <p>completed follow‐up of all randomised participants with long‐term follow‐up (at least 180 days).  </p> </li> </ul> </p> <p>Finally, the RCTs identified for this review investigated the effect of iron‐chelation therapy in spontaneous ICH. The effect of iron chelation in ischaemic stroke and subarachnoid haemorrhage remains to be determined. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009280-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009280-sec-0008"></div> <div class="table" id="CD009280-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Iron chelator versus placebo for adults with acute stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Iron chelator versus placebo for adults with acute stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patients or population:</b> adults with acute stroke </p> <p><b>Settings:</b> hospitals and clinical centres </p> <p><b>Intervention:</b> deferoxamine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk<br/>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk<br/>Deferoxamine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death from all causes at end of scheduled follow‐up</p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>180 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>291 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> did not describe any deaths. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8% (12/144)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8% (12/147)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Good neurological outcome (mRS 0 to 2)</p> <p>(follow‐up: 30 to 180 days)</p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>333 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>One small study had a follow‐up of 30 days (<a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a>), and one larger study had follow‐up at 90 and 180 days (<a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a>). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67% (14/21)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57% (12/21)</p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>90 days</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33% (47/143)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34% (48/140)</p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>180 days</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36% (48/135)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45% (61/135)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events (SAE)</p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>180 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81 (0.57 to 1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>291 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> found no SAEs and did not assess general adverse effects. </p> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> described one drug‐related SAE (ARDS). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33% (49/147)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27% (39/144)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any deaths within the treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> and <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> did not report on deaths within the treatment period. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Neurologic impairment scale at baseline and at the end of follow‐up (NIHSS)</p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>baseline mean (SD) to 30 days mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>333 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Low<sup>c</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> reported average NIHSS and standard deviations at baseline and at 30 days. No statistical tests were performed. </p> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> reported median NIHSS and interquartile range at baseline and at 90 days and tested for significance. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.7 (5.4) to <br/>2.8 (4.0) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9.1 (4.6) to<br/>3.2 (3.6) </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>baseline (median (IQR) to 90 days (median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.37</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 (9 to 19) to<br/>4 (2 to 7) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 (8 to 17) to<br/>3 (1 to 7) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Relative oedema volume</p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Postinfusion scan<sup>d</sup> median (IQR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>333 (2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> and <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> defined relative oedema volume as absolute oedema volume dived by haematoma volume.   </p> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> reported median changes in perilesional oedema and interquartile ranges. </p> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> reported average changes and standard deviations at 15 days. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.7 (0.3 to 1.2)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.9 (0.4 to 1.3)</p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>15 days, mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> P = 0.042</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.91 (1.94)   </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10.26 (17.54) <br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> and <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> did not report on quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>risk in the control group</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ARDS:</b> acute respiratory distress syndrome; <b>CI:</b> confidence interval; <b>DFO:</b> deferoxamine; <b>IQR</b> : interquartile range; <b>mRS</b> : Modified Rankin Scale; <b>NIHSS: </b> National Institutes of Health Stroke Scale; <b>RCT</b> : randomised controlled trial; <b>RR</b> : risk ratio; <b>SAE</b> : serious adverse event; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels for imprecision because of low number of studies with small sample size. </p> <p><sup>b</sup>Downgraded by two levels for imprecision because of low number of studies with small sample size and non‐congruent follow‐up times. </p> <p><sup>c</sup>Downgraded by two levels for imprecision because of low number of studies with low sample size, non‐congruent follow‐up times and non uniformity in reporting. </p> <p><sup>d</sup>Time of measurement varied slightly between the control group (73 h, IQR 69 to 78) and the experimental group (74 h, IQR 69 to 78). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009280-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009280-sec-0009"></div> <section id="CD009280-sec-0010"> <h3 class="title" id="CD009280-sec-0010">Description of the condition</h3> <p>Stroke is the second leading cause of death and a major cause of morbidity worldwide (<a href="./references#CD009280-bbs2-0022" title="GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology2019;18(5):439-58. [DOI: 10.1016/S1474-4422(19)30034-1] [PMID: 30871944]">Global Burden of Disease Study 2019</a>). Significant research efforts have been undertaken to develop pharmaceutical therapies for stroke, but only a few have revealed drugs that improve the prognosis of people who have had an acute stroke. In ischaemic stroke, tissue plasminogen activator (tPA) resolves clots and restores blood flow, but is only safe and beneficial if administered within a short therapeutic window (<a href="./references#CD009280-bbs2-0052" title="WardlawJM , MurrayV , BergeE ,  del ZoppoGJ . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD000213. [DOI: 10.1002/14651858.CD000213.pub3]">Wardlaw 2014</a>). Secondary prophylaxis with antiplatelet therapy improves the prognosis of people with acute ischaemic stroke by preventing the formation of new clots (<a href="./references#CD009280-bbs2-0047" title="SandercockPA , CounsellC , GubitzGJ . Antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews2008, Issue 3. Art. No: CD000029. [DOI: 10.1002/14651858.CD000029]">Sandercock 2008</a>). In subarachnoid haemorrhage (SAH), the calcium antagonist nimodipine has been shown to reduce the risk of poor outcome and secondary ischaemia (<a href="./references#CD009280-bbs2-0020" title="Dorhout MeesS , RinkelGJ , FeiginVL , AlgraA , vanden BerghWM , Vermeulen M et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database of Systematic Reviews2007, Issue 3. Art. No: CD000277. [DOI: 10.1002/14651858.CD000277.pub3]">Dorhout Mees 2007</a>). There is no pharmacological agent showing benefit in spontaneous intracerebral haemorrhage (ICH). Because of these limited therapeutic options, identification of new treatments to improve the clinical outcome of people with acute stroke is of great importance, both on a personal and public health level. </p> <p>In the last two decades, disturbances in iron homeostasis have been implicated as a contributing factor to neural damage following stroke. Free iron catalyses conversion of H<sub>2</sub>O<sub>2</sub> and O<sub>2</sub>‐  into highly reactive and toxic hydroxyl radicals (the Haber‐Weiss reaction), leading to a cascade of oxidative stress and cell death by apoptosis (<a href="./references#CD009280-bbs2-0016" title="CarbonellT ,  RamaR . Iron, oxidative stress and early neurological deterioration in ischemic stroke. Current Medicinal Chemistry2007;14(8):857-74. [DOI: 10.2174/092986707780363014]">Carbonell 2007</a>; <a href="./references#CD009280-bbs2-0048" title="SelimMH , RatanRR . The role of iron neurotoxicity in ischemic stroke. Ageing Research Reviews2004;3:345-53.">Selim 2004</a>). Haemoglobin degradation products resulting from thrombolysis and haemolysis after stroke cause an iron overload and catalyse the Haber‐Weiss reaction sequence, with neurotoxic effects (<a href="./references#CD009280-bbs2-0023" title="GoldsteinL , Teng Z-P, ZesersonE , PatelM , ReganRF . Hemin induces an iron-dependent, oxidative injury to human neuron-like cells. Journal of Neuroscience Research2003;73:113-21.">Goldstein 2003</a>). In ICH and SAH, haemoglobin degradation products exert the same effects.  </p> <p>Iron overload is also causally linked with endothelial damage (<a href="./references#CD009280-bbs2-0021" title="DuffySJ , BiegelsenES , HolbrookM , RussellJD , GokceN , Keaney JF Jr, et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation2001;103:2799-802.">Duffy 2001</a>), lipid peroxidation of the cell membrane (<a href="./references#CD009280-bbs2-0032" title="IshimaruH , IshikawaK , OheY , TakahashiA , TatemotoK , MaruyamaY . Activation of iron handling system within the gerbil hippocampus after cerebral ischemia. Brain Research1996;726:23-30.">Ishimaru 1996</a>), brain oedema (<a href="./references#CD009280-bbs2-0031" title="HuangF , XiG , KeepRF , HuaY , NemoianuA , HoffJT . Brain edema after experimental intracerebral hemorrhage: role of hemoglobin degradation products. Journal of Neurosurgery2002;96:287-93.">Huang 2002</a>), larger infarct volumes (<a href="./references#CD009280-bbs2-0017" title="CastellanosM , PuigN , CarbonellT , CastilloJ , MartinezJM , RamaR . Iron intake increases infarct volume after permanent middle cerebral artery occlusion in rats. Brain Research2002;952:1-6.">Castellanos 2002</a>), diabetes (<a href="./references#CD009280-bbs2-0046" title="SalonenJT , Tuomainen T-P, NyyssönenK , Lakka H-M, PunnonenK . Relation between iron stores and non-insulin dependent diabetes in men: case-control study. BMJ1998;317:727.">Salonen 1998</a>), inflammatory response exacerbation and ischaemic reperfusion injury following stroke (<a href="./references#CD009280-bbs2-0037" title="MehtaS , WebbRC , DorranceAM . The pathophysiology of ischemic stroke: a neuronal and vascular perspective. Journal of Medical Sciences2002;22:53-62.">Mehta 2002</a>). Clinical research also reveals that high serum ferritin levels are independently associated with poor outcome after ischaemic stroke (<a href="./references#CD009280-bbs2-0038" title="MillanM , SobrinoT , CastellanosM , NombelaF , ArenillasJF , RivaE . Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke. Stroke2007;38:90-5.">Millan 2007</a>), and after ICH (<a href="./references#CD009280-bbs2-0041" title="Pérez de la OssaP , SobrinoT , SilvaY , BlancoM , MillánM , GomisM . Iron-related brain damage in patients with intracerebral hemorrhage. Stroke2010;40:810-3.">Pérez de la Ossa 2010</a>). </p> </section> <section id="CD009280-sec-0011"> <h3 class="title" id="CD009280-sec-0011">Description of the intervention</h3> <p>Iron‐chelating drugs have been widely used for more than 40 years in people with iron overload diseases, such as haemochromatosis, thalassaemia, and sickle cell disease. These drugs bind excess iron and may reduce iron‐induced brain damage. Bound iron is inert and cannot perform in chemical reactions that lead to neurotoxic events (<a href="./references#CD009280-bbs2-0049" title="SelimM . Deferoxamine mesylate. a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke2009;40(3 Suppl):90-1.">Selim 2009</a>). The pharmacodynamics and pharmacokinetics of iron chelators are well known, since these drugs have been used safely for more than 40 years (<a href="./references#CD009280-bbs2-0042" title="PrabhuR , PrabhuV , PrabhuRS . Iron overload in beta thalassemia: a review. Journal of Bioscience and Technology2009;1:20-31.">Prabhu 2009</a>). </p> <p>Animal stroke models have demonstrated that iron chelators exert a neuroprotective effect, and preclinical research suggests that iron chelation can prevent damage from ischaemic stroke (<a href="./references#CD009280-bbs2-0026" title="HansonLR , RoeytenbergA , MartinezPM . Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. Journal of Pharmacology and Experimental Therapeutics2009;330:679-86.">Hanson 2009</a>), ICH (<a href="./references#CD009280-bbs2-0039" title="NakamuraT , KeepRF , HuaY , SchallertT , HoffJT , XiG . Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. Journal of Neurosurgery2004;100:672-8.">Nakamura 2004</a>), and SAH (<a href="./references#CD009280-bbs2-0015" title="ArthurAS ,  FergusAH ,  LanzinoG ,  MathysJ ,  KassellNF ,  LeeKS . Systemic administration of the iron chelator deferiprone attenuates subarachnoid hemorrhage-induced cerebral vasospasm in the rabbit. Neurosurgery1997;41(6):1385-91. [DOI: 10.1097/00006123-199712000-00028]">Arthur 1997</a>, <a href="./references#CD009280-bbs2-0034" title="LeeJY , KeepRF ,  HeY ,  SagherO ,  HuaY ,  XiG . Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury. Journal of Cerebral Blood Flow &amp; Metabolism 2010 Nov;30(11):1793-803. [DOI: 10.1038/jcbfm.2010.137]">Lee 2010</a>). </p> </section> <section id="CD009280-sec-0012"> <h3 class="title" id="CD009280-sec-0012">How the intervention might work</h3> <p>Iron‐chelating drugs work to bind excess iron in the blood and local tissues. The generation of hydroxyl radicals in the Haber‐Weiss reaction leads to extraction of hydrogen from unsaturated lipids in the cell membrane, and initiates lipid peroxidation (<a href="./references#CD009280-bbs2-0016" title="CarbonellT ,  RamaR . Iron, oxidative stress and early neurological deterioration in ischemic stroke. Current Medicinal Chemistry2007;14(8):857-74. [DOI: 10.2174/092986707780363014]">Carbonell 2007</a>; <a href="./references#CD009280-bbs2-0025" title="HalliwellB ,  GutteridgeJM . Oxygen toxicity, oxygen radicals, transition metals and disease. Biochemical Journal1984;219(1):1-14. [DOI: 10.1042/bj2190001]">Halliwell 1984</a>; <a href="./references#CD009280-bbs2-0048" title="SelimMH , RatanRR . The role of iron neurotoxicity in ischemic stroke. Ageing Research Reviews2004;3:345-53.">Selim 2004</a>). Additionally, it can exacerbate excitotoxicity by increased intracellular iron accumulation (<a href="./references#CD009280-bbs2-0018" title="DávalosA ,  CastilloJ ,  MarrugatJ ,  Fernandez-RealJM ,  ArmengouA ,  CacabelosP ,  et al. Body iron stores and early neurologic deterioration in acute cerebral infarction. Neurology2000;54(8):1568-74. [DOI: 10.1212/wnl.54.8.1568]">Dávalos 2000</a>; <a href="./references#CD009280-bbs2-0044" title="ReganRF ,  PanterSS . Hemoglobin potentiates excitotoxic injury in cortical cell culture. Journal of Neurotrauma1996;13(4):223-31. [DOI: 10.1089/neu.1996.13.223]">Regan 1996</a>). Iron‐chelating drugs can chelate ferric ion (Fe3+) and haemosiderin to form a stable and inert complex that prevents iron from entering the Haber‐Weiss reaction. As such, these drugs limit iron overload and iron‐mediated toxicity secondary to acute stroke (<a href="./references#CD009280-bbs2-0049" title="SelimM . Deferoxamine mesylate. a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke2009;40(3 Suppl):90-1.">Selim 2009</a>). </p> <p>The most studied iron chelator is deferoxamine (DFO). In acute ischaemic stroke animal models, this drug has been shown to induce tolerance against cerebral ischaemia (<a href="./references#CD009280-bbs2-0043" title="PrassK , RuscherK , KarschM , IsaevN , MegowD , PrillerJ . Deferoxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. Journal of Cerebral Blood Flow and Metabolism2002;22:520-5.">Prass 2002</a>), reduce brain swelling (<a href="./references#CD009280-bbs2-0053" title="XingY , HuaY , KeepRF , XiG . Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia. Brain Research2009;291:113-21.">Xing 2009</a>), decrease ischaemic volume (<a href="./references#CD009280-bbs2-0036" title="LiYX , DingSJ , XiaoL , GuoW , ZhanQ . Deferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. Neuroscience Bulletin2008;2:89-95.">Li 2008</a>), and reduce reperfusion injury (<a href="./references#CD009280-bbs2-0028" title="HatcherHC , SinghRN , TortiFM , TortiSV . Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Medicinal Chemistry2009;1:1643-70.">Hatcher 2009</a>). In acute haemorrhagic stroke animal models, DFO can reduce brain oedema (<a href="./references#CD009280-bbs2-0039" title="NakamuraT , KeepRF , HuaY , SchallertT , HoffJT , XiG . Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. Journal of Neurosurgery2004;100:672-8.">Nakamura 2004</a>), neurologic deficits (<a href="./references#CD009280-bbs2-0024" title="GuY , HuaY , KeepRF , MorgensternLB , XiG . Deferoxamine reduces intracerebral hematoma-induced iron accumulation and neuronal death in piglets. Stroke2009;40:2241-3.">Gu 2009</a>), and brain atrophy (<a href="./references#CD009280-bbs2-0040" title="OkauchiM , HuaY , KeepRF , MorgensternLB , SchallertT , XiG . Deferoxamine treatment for intracerebral hemorrhage in aged rats. Stroke2010;41:375.">Okauchi 2010</a>). In animal models of SAH, DFO reduces cerebral vasospasm and delayed cerebral ischaemia (<a href="./references#CD009280-bbs2-0034" title="LeeJY , KeepRF ,  HeY ,  SagherO ,  HuaY ,  XiG . Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury. Journal of Cerebral Blood Flow &amp; Metabolism 2010 Nov;30(11):1793-803. [DOI: 10.1038/jcbfm.2010.137]">Lee 2010</a>). In addition, iron chelators (DFO and deferasirox) also have the effect of neuroprotection and neurorepair in vitro (<a href="./references#CD009280-bbs2-0019" title="DexterDT , StattonSA , WhitmoreC , FreinbichlerW , WeinbergerP , TiptonKF . Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. Journal of Neural Transmission2011;118:223-31.">Dexter 2011</a>; <a href="./references#CD009280-bbs2-0054" title="ZamanK , RyuH , HallD . Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21 (waf1/cip1), and erythropoietin. Journal of Neuroscience1999;19:9821-30.">Zaman 1999</a>; <a href="./references#CD009280-bbs2-0055" title="ZhaoY , RempeDA . Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. Journal of Cerebral Blood Flow and Metabolism2011;31(6):1412-23. [DOI: 10.1038]">Zhao 2011</a>). </p> </section> <section id="CD009280-sec-0013"> <h3 class="title" id="CD009280-sec-0013">Why it is important to do this review</h3> <p>Despite the growing evidence from in vitro and animal models that has demonstrated the beneficial effect of iron‐chelating therapy in acute stroke, clinical evidence is still insufficient. A systematic analysis of all randomised controlled trials (RCTs) of iron chelation therapy for acute stroke is needed. Because of the high and increasing incidence of stroke, and its associated burden of disease and excessive costs, even a small improvement in favourable outcomes could have a major impact on health care. This is the first update of the original Cochrane Review published in 2012 (<a href="./references#CD009280-bbs2-0056" title="MaJ , YouC , HaoL . Iron chelators for acute stroke. Cochrane Database of Systematic Reviews2012, Issue 9. Art. No: CD009280. [DOI: 10.1002/14651858.CD009280.pub2]">Ma 2012</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009280-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009280-sec-0014"></div> <p>To evaluate the effectiveness and safety of iron‐chelating drugs in people with acute stroke. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009280-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009280-sec-0015"></div> <section id="CD009280-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009280-sec-0017"> <h4 class="title">Types of studies</h4> <p>Published and unpublished RCTs of iron chelator versus no iron chelator (or placebo) for the treatment of acute ischaemic stroke, intracerebral haemorrhage, or subarachnoid haemorrhage were eligible for inclusion. </p> </section> <section id="CD009280-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included participants of any age or sex with clinically diagnosed acute ischaemic stroke (cerebral infarction) or haemorrhagic stroke (ICH or aneurysmal subarachnoid haemorrhage). </p> </section> <section id="CD009280-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The intervention of interest was iron chelator versus no iron chelator or placebo, administered in any dose, by any route, for any duration and started within 48 hours after acute stroke. </p> </section> <section id="CD009280-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD009280-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009280-list-0001"> <li> <p>Death from all causes at end of scheduled follow‐up</p> </li> <li> <p>Good functional outcome: either no significant disability or slight disability with independence for assistance (dependency assessed at least one month after acute stroke) </p> </li> </ul> </p> <p>We defined independence as not being dependent on others for activities of daily living, for example having a Glasgow Outcome Scale (GOS) score of more than four (<a href="./references#CD009280-bbs2-0033" title="JennettB , BondM . Assessment of outcome after severe brain damage. Lancet1975;1:480-4.">Jennett 1975</a>), modified Rankin Scale (mRS) score of zero to two, and Barthel Index of 60 to 100 (<a href="./references#CD009280-bbs2-0050" title="SulterG , SteenC , De KeyserJ . Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke1999;30:1538-41.">Sulter 1999</a>). We used a minimum interval of one month to allow time for recovery from the initial stroke. </p> </section> <section id="CD009280-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009280-list-0002"> <li> <p>Any complications and (serious) adverse events (AEs) during the treatment and follow‐up periods (e.g. death, recurrent ICH or embolism, acute respiratory distress syndrome (ARDS), anaemia, unexplained worsening of neurologic status, hepatic or renal dysfunction, allergic reactions, phlebitis and hypotension). </p> </li> <li> <p>Any deaths within the treatment period</p> </li> <li> <p>Neurologic impairment scale at follow‐up periods (e.g. the National Institute of Health Stroke Scale (NIHSS), Canadian Neurological Scale, European Stroke Scale or the Scandinavian Stroke Scale; or any other scale that involves motor, sensory or other impaired neurologic function) </p> </li> <li> <p>Oedema volume surrounding haematoma or infarction</p> </li> <li> <p>Quality of life, if assessed by the included trials</p> </li> </ul> </p> </section> </section> </section> <section id="CD009280-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>See the methods for the Cochrane Stroke Group <a href="http://www.dcn.ed.ac.uk/csrg/entity/searchmethods.pdf" target="_blank">Specialised register</a>. </p> <section id="CD009280-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases.</p> <p> <ul id="CD009280-list-0003"> <li> <p>Cochrane Stroke Group Trials Register (last searched 2 September 2019)</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 9) in the Cochrane Library (last searched 26 August 2019) (<a href="./appendices#CD009280-sec-0069">Appendix 1</a>) </p> </li> <li> <p>MEDLINE Ovid (from 1950; last searched 2 September 2019) (<a href="./appendices#CD009280-sec-0070">Appendix 2</a>) </p> </li> <li> <p>Embase Ovid (from 1980; last searched 2 September 2019) (<a href="./appendices#CD009280-sec-0071">Appendix 3</a>) </p> </li> <li> <p>Web of Science: Science Citation Index Expanded (SCIEXPANDED) (last searched 2 September 2019) (<a href="./appendices#CD009280-sec-0072">Appendix 4</a>) </p> </li> </ul> </p> <p>We developed the MEDLINE search strategy using a combination of controlled vocabulary and free‐text terms with the help of the Cochrane Stroke Group Information Specialist and adapted it for the other databases. Where necessary, we combined these with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying RCTs and controlled clinical trials, as described in the Technical Supplement to Chapter 4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009280-bbs2-0035" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Technical supplement to Chapter 4: searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). The Cochrane Collaboration, 2019.. Available from: www.training.cochrane.org/handbook.">Lefebvre 2019</a>). </p> <p>We also searched the following ongoing trials registers (last searched 2 September 2019): </p> <p> <ul id="CD009280-list-0004"> <li> <p>Clinicaltrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>) (<a href="./appendices#CD009280-sec-0073">Appendix 5</a>); </p> </li> <li> <p>ISRCTN Registry (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>); </p> </li> <li> <p>Internet Stroke Center: The Stroke Trials Registry (<a href="http://www.strokecenter.org/trials" target="_blank">www.strokecenter.org/trials</a>); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>) (<a href="./appendices#CD009280-sec-0074">Appendix 6</a>). </p> </li> </ul> </p> </section> <section id="CD009280-sec-0025"> <h4 class="title">Searching other resources</h4> <p>In an effort to identify published, unpublished and ongoing trials, we:</p> <p> <ul id="CD009280-list-0005"> <li> <p>checked the reference lists of all relevant papers; and</p> </li> <li> <p>contacted researchers and study authors if necessary.</p> </li> </ul> </p> </section> </section> <section id="CD009280-sec-0026"> <h3 class="title" id="CD009280-sec-0026">Data collection and analysis</h3> <section id="CD009280-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (LL and RA) independently reviewed the titles, abstracts, and keywords of citations obtained from the searches of the electronic databases and excluded studies that were irrelevant (e.g. experimental stroke model, transfusion‐dependent patients and people with sickle cell disease). We obtained the full text of the remaining studies and the same two review authors independently assessed which trials met the predefined inclusion criteria with no disagreement. </p> </section> <section id="CD009280-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (LL and RA) independently extracted the following data from the included studies. </p> <p> <ul id="CD009280-list-0006"> <li> <p>Stroke type: ischaemic or haemorrhagic stroke (ICH or SAH)</p> </li> <li> <p>Methodological quality of each identified trial: sequence generation, allocation concealment, loss to follow‐up, blinding of outcome assessment </p> </li> <li> <p>Types of participants: inclusion and exclusion criteria, age, sex, similarity of groups at baseline, severity of stroke </p> </li> <li> <p>Interventions: type of iron chelator, duration, route of administration, with or without other combined treatment </p> </li> <li> <p>Types of outcomes</p> </li> <li> <p>Methods of analysis (intention‐to‐treat analysis or per‐protocol analysis, or both)</p> </li> <li> <p>Statistical methods used</p> </li> </ul> </p> </section> <section id="CD009280-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (LL and RA) assessed included RCTs using the 'Risk of bias' assessment tool as described in chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009280-bbs2-0029" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). We independently evaluated risk of bias through assessing: sequence generation, allocation concealment, blinding (we assessed each main outcome or class of outcomes), incomplete outcome data (we assessed each main outcome or class of outcomes), selective outcome reporting and other sources of bias. We created 'Risk of bias' tables including a judgement of 'low risk', 'high risk' or 'unclear risk' of bias for each domain. </p> </section> <section id="CD009280-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We intended to calculate the risk ratio (RR) and 95% confidence interval (CI) for dichotomous data, and the mean difference (MD) or standardised mean difference (SMD) and 95% CI for continuous outcomes. </p> </section> <section id="CD009280-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We excluded non‐standard designs, including cross‐over trials and cluster‐randomised trials. </p> </section> <section id="CD009280-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We planned to contact study authors to obtain any information missing from published reports. </p> </section> <section id="CD009280-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We intended to examine statistical heterogeneity with the I<sup>2</sup> statistic. We considered substantial heterogeneity existed if I<sup>2</sup> &gt; 50%. If there was substantial heterogeneity, we would look for the potential sources of the heterogeneity using preplanned subgroup analyses.  </p> </section> <section id="CD009280-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to undertake funnel plots to detect the existence of possible publication bias, as described in chapter 13 of the <i>Cochrane Handbook</i> (<a href="./references#CD009280-bbs2-0030" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). The Cochrane Collaboration, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>), if the number of included studies was sufficient (defined as 10 or more included studies). </p> </section> <section id="CD009280-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We intended to calculate the RRs and 95% CIs for dichotomous outcomes and calculate the MD or SMD and 95% CIs for continuous outcomes using a fixed‐effect model if there was no evidence of statistical heterogeneity. Otherwise, we would use the random‐effects model. We intended to perform all analyses using the Review Manager software RevMan Web (<a href="./references#CD009280-bbs2-0045" title="The Cochrane CollaborationReview Manager Web (RevMan Web). Version 1.23.2. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>). </p> </section> <section id="CD009280-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to perform the following subgroup analyses, where possible:</p> <p> <ul id="CD009280-list-0007"> <li> <p>stroke subtypes: ischaemic stroke participants only, ICH participants only; SAH only;</p> </li> <li> <p>type and dose of iron chelator; and</p> </li> <li> <p>the route of medication administration.</p> </li> </ul> </p> </section> <section id="CD009280-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out sensitivity analysis to explore the influence of study design and to determine the impact of studies with lower methodological quality, while excluding: </p> <p> <ul id="CD009280-list-0008"> <li> <p>studies at high risk of bias for blinding; and</p> </li> <li> <p>unpublished data.</p> </li> </ul> </p> </section> <section id="CD009280-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We summarised the findings in <a href="./full#CD009280-tbl-0001">summary of findings Table 1</a> using the GRADE approach as described in chapter 14 of the <i>Cochrane Handbook</i> (<a href="./references#CD009280-bbs2-0030" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). The Cochrane Collaboration, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). We included the following outcomes: </p> <p> <ul id="CD009280-list-0009"> <li> <p>death from all causes at end of scheduled follow‐up;</p> </li> <li> <p>good neurological outcome (follow‐up: 30 to 180 months);</p> </li> <li> <p>serious adverse events;</p> </li> <li> <p>any deaths within the treatment period;</p> </li> <li> <p>neurologic impairment scale at baseline and at the end of follow‐up;</p> </li> <li> <p>relative oedema volume; and</p> </li> <li> <p>quality of life.</p> </li> </ul> </p> <p>We downgraded the certainty of evidence using the five GRADE domains: study limitations, imprecision, inconsistency, indirectness, and publication bias. We justified all decisions to downgrade the certainty of evidence using footnotes. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009280-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009280-sec-0039"></div> <section id="CD009280-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD009280-sec-0041"> <h4 class="title">Results of the search</h4> <p>The updated electronic search strategies identified 452 records from English and other language databases, as well as cross‐references of included trials and other systematic reviews. At the end of our search, we had 390 records after duplicates were removed. We discarded 376 and requested full‐text copies of 14 references. Eight of these were trial protocols (of which six were <a href="./references#CD009280-sec-0083" title="">Characteristics of ongoing studies</a>), so we excluded them. Of the remaining five studies, we excluded four. We identified two studies (with 333 participants) that met the inclusion criteria and included them in this review (<a href="#CD009280-fig-0001">Figure 1</a>). For details of the studies we examined and the reasons we included or excluded them, see the <a href="./references#CD009280-sec-0081" title="">Characteristics of included studies</a> and <a href="./references#CD009280-sec-0082" title="">Characteristics of excluded studies</a> tables. </p> <div class="figure" id="CD009280-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD009280-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/image_n/nCD009280-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>In the original review, two studies were included (<a href="./references#CD009280-bbs2-0005" title="NCT00777140. Thrombolysis and deferoxamine in middle cerebral artery occlusion (TANDEM-1). clinicaltrials.gov/ct2/show/NCT00777140 (first received 22 October 2008). ">NCT00777140</a>; <a href="./references#CD009280-bbs2-0007" title="SelimM , YeattsS , GoldsteinJN , GomesJ , GreenbergS , MorgensternLB . Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke2011;42:3067-74. ">Selim 2011</a>). In the initial selection phase, we excluded these two studies because they did not meet the inclusion criteria. We reported our exclusion criteria in the <a href="./references#CD009280-sec-0082" title="">Characteristics of excluded studies</a> section. </p> </section> <section id="CD009280-sec-0042"> <h4 class="title">Included studies</h4> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> was a multicentre, randomised, placebo‐controlled, double‐blind phase 2 trial to assess the efficacy and safety of DFO in participants with ICH and to establish whether the drug merits investigation in a phase 3 trial. The trial randomised a total of 294 participants with spontaneous supratentorial ICH as confirmed by computed tomography (CT): 145 in the DFO group and 149 in the placebo group. Treatment was initiated in 144 participants in the DFO group and in 147 participants in the placebo group and all these 291 patients were included in analysis. DFO dose was 32 mg/kg for three consecutive days. Treatment was initiated within 24 hours. Participants in both groups received the same supportive treatment. The primary endpoint was mRS of 0 to 2 at day 90. Secondary endpoints were mRS 0 to 3 at day 90, mRS 0 to 2 and 0 to 3 at day 180, effect of treatment ≤ 12 hours vs &gt; 12 hours from onset, change in NIHSS from presentation to day 90, and Montreal Cognitive Assessment (MoCA) scores at day 90. At day 90, 97% of all participants in both groups had available data. </p> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> was a single‐centre, double‐blind, randomised, placebo‐controlled clinical trial to assess the efficacy of DFO for oedema resolution and haematoma absorption after ICH. This study randomised 42 people with spontaneous ICH as confirmed by CT: 21 participants in the DFO group and 21 in the placebo group. Participants in the DFO group received intravenous injection of DFO 32 mg/kg daily from the first admission day for three consecutive days (based on the dose‐finding study <a href="./references#CD009280-bbs2-0007" title="SelimM , YeattsS , GoldsteinJN , GomesJ , GreenbergS , MorgensternLB . Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke2011;42:3067-74. ">Selim 2011</a>). Participants in both groups received the same supportive treatment. The primary endpoint was relative oedema volume on the fifteenth day (or discharge), calculated using the ABC/2 method where relative oedema volume = absolute oedema volume/haematoma volume. Secondary endpoints were mRS on the fifteenth and the thirtieth day. </p> </section> <section id="CD009280-sec-0043"> <h4 class="title">Excluded studies</h4> <p><a href="./references#CD009280-bbs2-0003" title="CookDA , VollrathB . Free-radicals and intracellular events associated with cerebrovascular spasm. Cardiovascular Research1995;30(4):493-500. [PMID: 8574997]">Cook 1995</a> is a review article describing the role of different pathophysiological factors that contribute to cerebral vasospasm, including the role oxyhaemoglobin and various intracellular processes. </p> <p><a href="./references#CD009280-bbs2-0004" title="HaradaT , LuoZ , LondonS , GajdusekC , MaybergM . Antioxidant and iron-chelating agents in cerebral vasospasm. In: FindlayJM , editors(s). Cerebral Vasospasm. Amsterdam: Elsevier, 1993. ">Harada 1993</a> compared DFO with two antioxidants without iron‐chelating properties (ascorbic acid and U74389F) in rats. We excluded this study because it was a non‐human study. </p> <p><a href="./references#CD009280-bbs2-0006" title="PapadakisM , NagelS , BuchanAM . Development and efficacy of NXY-059 for the treatment of acute ischemic stroke. Future Neurology2008;3(3):229-40. [DOI: 10.2217/14796708.3.3.229]">Papadakis 2008</a> was a phase 3 study investigating the neuroprotective compound NXY‐059, which is not an iron‐chelating drug. Although NXY‐059 showed positive results in this phase 3 study, a larger scale phase 3 study revealed that the efficacy of NXY‐059 is not better than placebo in treating people with acute stroke (ischaemic and ICH). Hence, NXY‐059 failed to materialize as an effective acute stroke treatment. We excluded this study because it did not investigate iron‐chelating drugs. </p> <p><a href="./references#CD009280-bbs2-0008" title="Yeats SD, PaleschYY , MoyCS , SelimM . High dose deferoxamine in intracerebral hemorrhage (Hi-Def) trial: rationale, design, and methods. Neurocritical Care2013;192(2):257-66. ">Yeats 2013</a> was the trial protocol of the Hi‐DEF trial in which people with spontaneous ICH were randomised in high‐dose DFO or placebo. </p> <p>Selim 2011 was a multicentre, phase 1, dose‐finding study to assess the tolerability and safety of DFO in people with ICH, and to determine the maximum tolerated dose to be investigated in future studies. We excluded this study because the control group was varying doses of DFO. </p> <p><a href="./references#CD009280-bbs2-0005" title="NCT00777140. Thrombolysis and deferoxamine in middle cerebral artery occlusion (TANDEM-1). clinicaltrials.gov/ct2/show/NCT00777140 (first received 22 October 2008). ">NCT00777140</a> (TANDEM‐1 trial) was a double‐blind, randomised, placebo‐controlled, dose‐finding phase 2 clinical trial that intended to enrol 60 participants to evaluate the safety and tolerability of intravenous infusion of DFO in people with acute ischaemic stroke treated with tPA. This dose‐finding study investigated three different doses of DFO (10 mg/kg intravenous bolus followed by a 72‐hour continuous intravenous infusion) in three steps: </p> <p> <ul id="CD009280-list-0010"> <li> <p>first step: bolus 10 mg/kg plus 20 mg/kg/day versus placebo (20 participants: 15 actives versus five placebo); </p> </li> <li> <p>second step: bolus 10 mg/kg plus 40 mg/kg/day versus placebo (20 participants: 15 actives versus five placebo); and </p> </li> <li> <p>third step: bolus 10 mg/kg plus 60 mg/kg/day versus placebo (20 participants: 15 actives versus five placebo). </p> </li> </ul> </p> <p>The TANDEM‐1 trial has not been updated since 2012. We excluded this study because this was a trial protocol of a dose‐finding study using varying doses of DFO. </p> <section id="CD009280-sec-0044"> <h5 class="title">Ongoing studies</h5> <p><a href="./references#CD009280-bbs2-0012" title="NCT02216513. Deferoxamine to prevent delayed cerebral ischemia after subarachnoid hemorrhage. clinicaltrials.gov/ct2/show/NCT02216513 (first received 15 August 2014). ">NCT02216513</a>, <a href="./references#CD009280-bbs2-0013" title="NCT02875262. Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial (DASH). clinicaltrials.gov/ct2/show/NCT02875262 (first received 23 August 2016). ">NCT02875262</a>, and <a href="./references#CD009280-bbs2-0014" title="NCT03754725. Deferiprone for ruptured brain aneurysm. clinicaltrials.gov/ct2/show/NCT03754725 (first received 27 November 2018). ">NCT03754725</a>  are ongoing trials investigating the effect of iron chelators after subarachnoid haemorrhage. </p> <p><a href="./references#CD009280-bbs2-0009" title="ChiCTR-TRC-14004979. The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. www.chictr.org.cn/showprojen.aspx?proj=4595 (first received 20 July 2014). ">ChiCTR‐TRC‐14004979</a> is an ongoing trial investigating the clinical effect of DFO on oedema after intracerebral haemorrhage. </p> <p><a href="./references#CD009280-bbs2-0010" title="EUCTR2007-006731-31-ES 2008. Double-blind, randomized, placebo controlled, dose-finding phase II clinical trial of intravenous deferoxamine in patients with acute ischemic stroke treated with tissue plasminogen activator. www.clinicaltrialsregister.eu/ctr-search/trial/2007-006731-31/ES (first received 1 January 2008). ">EUCTR2007‐006731‐31‐ES</a> and <a href="./references#CD009280-bbs2-0011" title="IRCT2013111915444N2. Effect of deferoxamine on hemorrhagic transformation of middle cerebral artery stroke. www.irct.ir/trial/14703 (first received 12 November 2014). ">IRCT2013111915444N2</a> are trials investigating the effect of iron chelators after ischaemic stroke. </p> </section> </section> </section> <section id="CD009280-sec-0045"> <h3 class="title">Risk of bias in included studies</h3> <p>We documented the risk of bias for included studies based on the full‐text articles. Wherever there was a need for clarification, we tried contacting the authors. Based on the available data, we assessed the risk of bias as low, high or unclear. We assessed one trial to be at low risk of bias (<a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a>), and the other one to be at high risk of bias (<a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a>). See 'Risk of bias' tables within <a href="http://Characteristics of included studies" target="_blank">Characteristics of included studies</a> for further details. For a graphical summary, see <a href="#CD009280-fig-0002">Figure 2</a> and <a href="#CD009280-fig-0003">Figure 3</a>.  </p> <div class="figure" id="CD009280-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across the included studies" data-id="CD009280-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/image_n/nCD009280-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across the included studies </p> </div> </div> </div> <div class="figure" id="CD009280-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD009280-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/image_n/nCD009280-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD009280-sec-0046"> <h4 class="title">Allocation</h4> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> adequately reported the method of sequence generation and concealment of allocation, through a combination of minimisation and biased coin methods. Participants were enrolled by a web‐based trial management system and randomly allocated (1:1) to the intervention or the control group. We assessed this as a low risk of bias. </p> <p>In <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a>, a random table of group information was established in the design phase before participant enrolment according to the sequence of the participants enrolled. We assessed this as a high risk of bias. </p> </section> <section id="CD009280-sec-0047"> <h4 class="title">Blinding</h4> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> reported blinding of participants and personnel. The trial medication and the placebo were matched to look identical. The only person not blinded was the pharmacist, who was not involved in any study‐related assessments. All assessors were blinded. We assessed this as low risk of both performance and detection bias. </p> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> reported blinding participants and relatives, but did not explicitly report on blinding of caregivers. This introduces a high risk of performance bias, because participants in the intervention group received intravenous injections whereas participants in the control group did not. The outcome assessment and all assessors were blinded. Therefore, we deemed the risk of detection bias to be low. </p> </section> <section id="CD009280-sec-0048"> <h4 class="title">Incomplete outcome data</h4> <p>Both <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> and <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> adequately described participants' attrition. <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> classified three participants as postrandomisation exclusions and excluded them from the analysis. This led to a modified intention‐to‐treat population of 291 instead of 294 participants. In the DFO group, the trialists excluded four participants (one withdrew consent, one was lost to follow‐up and two had data collected outside the prespecified data collection window). In the control group, the trialists excluded four participants (two withdrew consent, one was lost to follow‐up and one had data collected outside the window). We considered this to be a low loss to follow‐up (2.7%). </p> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> randomised 42 participants, and all of them completed the 30 day follow‐up. The trial did not report any dropouts, and reported outcomes for all randomised participants. </p> <p>We assessed risk of attrition bias to be low in both studies.</p> </section> <section id="CD009280-sec-0049"> <h4 class="title">Selective reporting</h4> <p>Both <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> and Yu 2015 reported on all outcomes specified in the methods section of the manuscripts, either in the results section or the supplementary files. <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> was a registered study. All outcome parameters mentioned in the manuscript had also been mentioned in the protocol. We assessed the risk of reporting bias to be low. <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> was a registered study; however, the protocol did not specify any outcome measures. This introduced a high risk of reporting bias. We also considered the retrospective registration of the trial protocol to introduce a risk of reporting bias. </p> </section> <section id="CD009280-sec-0050"> <h4 class="title">Other potential sources of bias</h4> <p>We have no reason to assume other sources of bias in the study by <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a>. The registered trial protocol for the <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> study was updated after the paper was received by the publishing journal. This retrospective registration introduced a high risk of bias. </p> </section> </section> <section id="CD009280-sec-0051"> <h3 class="title" id="CD009280-sec-0051">Effects of interventions</h3> <p>See: <a href="./full#CD009280-tbl-0001"><b>Summary of findings 1</b> Iron chelator versus placebo for adults with acute stroke</a> </p> <p>Please see <a href="./full#CD009280-tbl-0001">summary of findings Table 1</a> for an overview of results. </p> <section id="CD009280-sec-0052"> <h4 class="title">Deaths</h4> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> reported that 10 of 144 (6.9%) participants in the DFO group and 11 of 147 (7.5%) in the placebo group had died by day 90, and by day 180 total mortality was 12 of 144 (8.3%) in the DFO group and 12 of 147 (8.2%) in the control group (P = 0.956); none of the deaths were judged to be treatment related. <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> described four deaths in the DFO group and two in the placebo group in the first seven days. The treatment period was three days and no assumptions can be made about the fraction of participants that died in the treatment period.  </p> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> did not report any deaths in either the DFO and the placebo group. </p> </section> <section id="CD009280-sec-0053"> <h4 class="title">Clinical outcome</h4> <p>Both <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> and <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> investigated clinical outcome, with the same definition of good clinical outcome (mRS 0 to 2). As a secondary endpoint, <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> also investigated the proportion of participants with a mRS score 0 to 3. However, the timing of this endpoint was different in the two studies (15 and 30 days in <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a>, ​​and 90 and 180 days in <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a>). This precluded quantitative analysis. </p> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a>​​​​​ found no difference in good clinical outcome between the DFO and the placebo group at 15 days (mRS 0‐2: DFO group 47.6%, control group 52.4%, P = 0.758). There was also no difference between the two groups at 30 days (mRS 0‐2: DFO group 57.1%, control group 66.7%; P = 0.525). Glasgow Outcome Score (GOS) improved from 3.0 ± 0.2 at baseline to 4.3 ± 0.9 at 30 days in the DFO group and from 3.1 ± 0.3 to 4.5 ± 0.9 in the placebo group. Barthel Index (BI) score improved from 60.7 ± 32.8 at baseline to 79.5 ± 28.1 at 30 days in the DFO group and from 66.9 ± 31.6 to 80.5 ± 31.9 in the placebo group. No statistical tests were done on GOS and BI scores. </p> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> found no difference in good clinical outcome between the DFO and placebo group at both 90 and 180 days, regardless of the definition of good clinical outcome (mRS 0 to 2 or mRS 0 to 3). At 90 days, 34% (48 of 140) of patients in the DFO group had mRS scores of 0 to 2, and this score was reported for 33% (47 of 143) in the placebo group. This difference fell below the prespecified 12% futility threshold. In secondary analysis, 45% (61 of 135) of participants in the DFO group and 36% (48 of 135) in the placebo group had mRS scores of 0 to 2 at day 180. Sixty‐five per cent (91 of 140) of participants in the DFO mesylate group and 57% (82 of 143) of participants in the placebo group had mRS scores of 0 to 3 at day 90. Seventy‐two per cent (97 of 135) of participants in the DFO group and 68% (92 of 135) of participants in the placebo group had mRS scores of 0 to 3 at day 180. The results of <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> suggest that a large phase 3 trial would be futile (in terms of the proportion of participants with good clinical outcome (mRS 0 to 2 at day 90). Secondary analysis left open the possibility that DFO might not be futile in terms of good clinical outcome at day 180 and should be investigated further. </p> </section> <section id="CD009280-sec-0054"> <h4 class="title">Safety and tolerability</h4> <p>In <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a>, there were no SAEs related to DFO use. General adverse events were not reported. <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> reported all AEs and SAEs. In the placebo group, 49 of 147 participants (33%) suffered serious adverse events (SAEs), compared with 39 of 144 (27%) in the DFO group (relative risk 0.81 (95% CI 0.57 to 1.16). A special mention of ARDS is made, and two cases (1%) were reported in the DFO group. One of these cases was possibly related to the study drug. Both studies concluded that the administration of DFO was safe. </p> </section> <section id="CD009280-sec-0055"> <h4 class="title">Neurologic impairment</h4> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> reported no difference in NIHSS scores at 90 days. Median NIHSS scores improved from 13 (interquartile range (IQR) 8 to 17) at baseline to 3 (IQR 1 to 7) at 90 days in the DFO group and from 13 (IQR 9 to 19) at baseline to 4 (IQR 2 to 7) in the placebo group (P = 0.37). </p> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> reported average NIHSS and standard deviation at baseline (9.1 ± 4.6 in the DFO group and 8.7 ± 5.4 in the placebo group) and at 30 days (3.2 ± 3.6 in the DFO group and 2.8 ± 4.0 in the placebo group). The trialists did not report any statistical tests. </p> </section> <section id="CD009280-sec-0056"> <h4 class="title">Oedema formation and absorption of the haematoma</h4> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> reported higher haematoma absorption in the placebo group than in the DFO group from day one to day eight (relative absorption DFO group 0.21, control group 0.41; P = 0.006), and from day eight to day 15 (relative absorption DFO group 0.55, control group 0.79; P = 0.004). The relative oedema volume on the fifteenth day (or discharge) in the placebo group was higher than the relative oedema volume in the DFO group (mean ± standard deviation was 10.26 ± 17.54 vs. 1.91 ± 1.94, P = 0.042). The results of <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> suggest that DFO can slow down the absorption of haematoma after ICH and prevent the formation of oedema.  </p> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> reported that there was there was no difference in changes in relative perilesional oedema: DFO group 0.7 (0.3 to 1.2); control group 0.9 (0.4 to 1.3). Up to 12 hours, relative perilesional oedema increased by 0.28 in the DFO group and 0.83 in the placebo group. Meta‐analysis was not possible. </p> </section> <section id="CD009280-sec-0057"> <h4 class="title">Quality of life</h4> <p>Neither <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> nor <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> reported on quality of life measurements. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009280-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009280-sec-0058"></div> <section id="CD009280-sec-0059"> <h3 class="title" id="CD009280-sec-0059">Summary of main results</h3> <p>In addition to the first edition of this review (<a href="./references#CD009280-bbs2-0056" title="MaJ , YouC , HaoL . Iron chelators for acute stroke. Cochrane Database of Systematic Reviews2012, Issue 9. Art. No: CD009280. [DOI: 10.1002/14651858.CD009280.pub2]">Ma 2012</a>), we have included two new RCTs that compare the effect of DFO with placebo in participants with spontaneous intracerebral haemorrhage (<a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a>; <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a>). We have excluded the two studies analysed qualitatively in the first edition (<a href="./references#CD009280-bbs2-0007" title="SelimM , YeattsS , GoldsteinJN , GomesJ , GreenbergS , MorgensternLB . Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke2011;42:3067-74. ">Selim 2011</a>; <a href="./references#CD009280-bbs2-0005" title="NCT00777140. Thrombolysis and deferoxamine in middle cerebral artery occlusion (TANDEM-1). clinicaltrials.gov/ct2/show/NCT00777140 (first received 22 October 2008). ">NCT00777140</a>). The limited number of studies and their heterogeneity precluded meta‐analysis. Neither of the studies demonstrated difference in good clinical outcome between groups. Both studies concluded that administration of DFO was safe. <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> demonstrated higher oedema absorption after 15 days, but <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> found no difference in changes in relative perilesional oedema </p> <p>There were no studies investigating the effect of iron chelation therapy in acute ischaemic stroke or subarachnoid haemorrhage. </p> </section> <section id="CD009280-sec-0060"> <h3 class="title" id="CD009280-sec-0060">Overall completeness and applicability of evidence</h3> <p>The limited evidence presented in this review does not allow us to draw any conclusions about the effect of DFO in people with stroke in general. Insufficient data also restricted potential subgroup analyses in participants with spontaneous intracerebral haemorrhage. In light of all the information provided above, the applicability of our findings is limited. </p> </section> <section id="CD009280-sec-0061"> <h3 class="title" id="CD009280-sec-0061">Quality of the evidence</h3> <p>We assessed the certainty of the evidence presented in this review using the GRADE approach, and have presented this information in <a href="./full#CD009280-tbl-0001">summary of findings Table 1</a>. We graded the certainty of evidence to be low across outcomes. The limited number of studies and their heterogeneity precluded meta‐analysis. We assessed the risk of bias in <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> to be 'low'. In <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a>, there were potential sources of bias leading to selection bias, performance bias and reporting bias. We assessed attrition and detection bias to be low. </p> <p>We assessed the evidence about death from all causes to be of low certainty. Case fatality was very low in the two included studies, suggesting that they excluded people with ICH who had severe signs at stroke onset (both <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> and <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> excluded people with GCS scores &lt; 5, and <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> also excluded people with NIHSS scores &lt; 6). The certainty of evidence was downgraded because of this possible indirectness. </p> <p>We assessed the evidence for good neurological outcome to be of low certainty. Follow‐up duration varied greatly between 30 and 180 days, and we only included two studies. The certainty of evidence was downgraded because of this inconsistency and the small number of studies included. </p> <p>We assessed the evidence for serious adverse events to be of low certainty. <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> found no serious adverse events and <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> reported one event. The certainty of evidence was downgraded because of the small number of studies and events reported. </p> <p>We assessed the evidence for neurological impairment to be of low certainty. Both included studies reported on this outcome parameter, but there was no uniformity in reporting, precluding meta‐analysis. The certainty of evidence was lowered because of inconsistency and the small number of studies included. </p> <p>We assessed the evidence for perilesional oedema to be of low certainty. Both included studies reported on this outcome parameter, but there was no uniformity in reporting. The certainty of evidence was downgraded because of inconsistency and the small number of studies included. </p> <p>We did not assess the certainty of evidence for the quality of life outcome, as no study reported this. </p> </section> <section id="CD009280-sec-0062"> <h3 class="title" id="CD009280-sec-0062">Potential biases in the review process</h3> <p>We conducted this review in accordance with established Cochrane standards. Two review authors independently assessed the search results and resolved any discrepancies by discussion or by consultation with a third review author.  We did not restrict the search by language. Two review authors extracted data from all included studies and resolved any discrepancies by discussion or by consultation with a third review author. We may have missed some unpublished data, owing to a relatively large number of ongoing trials where we could not contact study authors. </p> </section> <section id="CD009280-sec-0063"> <h3 class="title" id="CD009280-sec-0063">Agreements and disagreements with other studies or reviews</h3> <p>The two included studies were the only RCTs in which DFO and placebo were compared in people.  </p> <p>In animal studies, DFO was found to decrease perilesional oedema ​​​​​​(<a href="./references#CD009280-bbs2-0039" title="NakamuraT , KeepRF , HuaY , SchallertT , HoffJT , XiG . Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. Journal of Neurosurgery2004;100:672-8.">Nakamura 2004</a>; <a href="./references#CD009280-bbs2-0053" title="XingY , HuaY , KeepRF , XiG . Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia. Brain Research2009;291:113-21.">Xing 2009</a>), and neurological deficits (<a href="./references#CD009280-bbs2-0024" title="GuY , HuaY , KeepRF , MorgensternLB , XiG . Deferoxamine reduces intracerebral hematoma-induced iron accumulation and neuronal death in piglets. Stroke2009;40:2241-3.">Gu 2009</a>). One of the included RCTs showed that the perilesional oedema volume was lower in the DFO group (<a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a>), but a difference in neurological deficit could not be demonstrated. <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> did not find a clear effect of DFO on the growth of relative oedema. </p> <p>The use of iron chelators for SAH has been subject of animal studies with promising results on reduced vasospasm, oxidative stress, neuronal cell death and mortality (<a href="./references#CD009280-bbs2-0015" title="ArthurAS ,  FergusAH ,  LanzinoG ,  MathysJ ,  KassellNF ,  LeeKS . Systemic administration of the iron chelator deferiprone attenuates subarachnoid hemorrhage-induced cerebral vasospasm in the rabbit. Neurosurgery1997;41(6):1385-91. [DOI: 10.1097/00006123-199712000-00028]">Arthur 1997</a>; <a href="./references#CD009280-bbs2-0027" title="HaradaT , MaybergMR . Inhibition of delayed arterial narrowing by the iron-chelating agent deferoxamine. Journal of Neurosurgery1992;77:763-7.">Harada 1992</a>; <a href="./references#CD009280-bbs2-0034" title="LeeJY , KeepRF ,  HeY ,  SagherO ,  HuaY ,  XiG . Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury. Journal of Cerebral Blood Flow &amp; Metabolism 2010 Nov;30(11):1793-803. [DOI: 10.1038/jcbfm.2010.137]">Lee 2010</a>; <a href="./references#CD009280-bbs2-0051" title="VollmerDG , HongoK , OgawaH , TsukaharaT , KassellNF . A study of the effectiveness of the iron-chelating agent deferoxamine as vasospasm prophylaxis in a rabbit model of subarachnoid hemorrhage. Neurosurgery1991;28:27-32.">Vollmer 1991</a>). No clinical study for the use of DFO in aneurysmal subarachnoid haemorrhage has been performed, although several trials are proposed (<a href="./references#CD009280-bbs2-0012" title="NCT02216513. Deferoxamine to prevent delayed cerebral ischemia after subarachnoid hemorrhage. clinicaltrials.gov/ct2/show/NCT02216513 (first received 15 August 2014). ">NCT02216513</a>; <a href="./references#CD009280-bbs2-0013" title="NCT02875262. Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial (DASH). clinicaltrials.gov/ct2/show/NCT02875262 (first received 23 August 2016). ">NCT02875262</a>; <a href="./references#CD009280-bbs2-0014" title="NCT03754725. Deferiprone for ruptured brain aneurysm. clinicaltrials.gov/ct2/show/NCT03754725 (first received 27 November 2018). ">NCT03754725</a>). <a href="./references#CD009280-bbs2-0028" title="HatcherHC , SinghRN , TortiFM , TortiSV . Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Medicinal Chemistry2009;1:1643-70.">Hatcher 2009</a> and <a href="./references#CD009280-bbs2-0036" title="LiYX , DingSJ , XiaoL , GuoW , ZhanQ . Deferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. Neuroscience Bulletin2008;2:89-95.">Li 2008</a> described animal studies investigating ischaemic stroke, but we did not identify any studies in humans. </p> <p>A safety study for the use of DFO in people with intracerebral haemorrhage (ICH) has been performed (<a href="./references#CD009280-bbs2-0007" title="SelimM , YeattsS , GoldsteinJN , GomesJ , GreenbergS , MorgensternLB . Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke2011;42:3067-74. ">Selim 2011</a>). This study revealed the tolerability and safety of DFO in doses up to 62 mg/kg/day and up to a maximal dose of 6000 mg/day in people with ICH administered for three days. The included study by <a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> built upon this earlier work. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009280-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/urn:x-wiley:14651858:media:CD009280:CD009280-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD009280-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/image_n/nCD009280-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/image_t/tCD009280-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/full#CD009280-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/image_n/nCD009280-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009280-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/urn:x-wiley:14651858:media:CD009280:CD009280-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across the included studies" data-id="CD009280-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/image_n/nCD009280-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/image_t/tCD009280-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across the included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/full#CD009280-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/image_n/nCD009280-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009280-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/urn:x-wiley:14651858:media:CD009280:CD009280-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD009280-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/image_n/nCD009280-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/image_t/tCD009280-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/full#CD009280-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/media/CDSR/CD009280/image_n/nCD009280-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009280-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Iron chelator versus placebo for adults with acute stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Iron chelator versus placebo for adults with acute stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patients or population:</b> adults with acute stroke </p> <p><b>Settings:</b> hospitals and clinical centres </p> <p><b>Intervention:</b> deferoxamine </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk<br/>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk<br/>Deferoxamine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death from all causes at end of scheduled follow‐up</p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>180 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>291 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> did not describe any deaths. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8% (12/144)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8% (12/147)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Good neurological outcome (mRS 0 to 2)</p> <p>(follow‐up: 30 to 180 days)</p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>333 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>One small study had a follow‐up of 30 days (<a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a>), and one larger study had follow‐up at 90 and 180 days (<a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a>). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67% (14/21)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57% (12/21)</p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>90 days</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33% (47/143)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34% (48/140)</p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>180 days</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36% (48/135)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45% (61/135)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events (SAE)</p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>180 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81 (0.57 to 1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>291 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> found no SAEs and did not assess general adverse effects. </p> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> described one drug‐related SAE (ARDS). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33% (49/147)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27% (39/144)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any deaths within the treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> and <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> did not report on deaths within the treatment period. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Neurologic impairment scale at baseline and at the end of follow‐up (NIHSS)</p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>baseline mean (SD) to 30 days mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>333 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Low<sup>c</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> reported average NIHSS and standard deviations at baseline and at 30 days. No statistical tests were performed. </p> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> reported median NIHSS and interquartile range at baseline and at 90 days and tested for significance. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.7 (5.4) to <br/>2.8 (4.0) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9.1 (4.6) to<br/>3.2 (3.6) </p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>baseline (median (IQR) to 90 days (median (IQR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.37</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 (9 to 19) to<br/>4 (2 to 7) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 (8 to 17) to<br/>3 (1 to 7) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Relative oedema volume</p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Postinfusion scan<sup>d</sup> median (IQR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>333 (2 RCTs)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> and <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> defined relative oedema volume as absolute oedema volume dived by haematoma volume.   </p> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> reported median changes in perilesional oedema and interquartile ranges. </p> <p><a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> reported average changes and standard deviations at 15 days. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.7 (0.3 to 1.2)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.9 (0.4 to 1.3)</p> </td> </tr> <tr class="separated"> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>15 days, mean (SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> P = 0.042</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1.91 (1.94)   </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10.26 (17.54) <br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009280-bbs2-0001" title="SelimM , FosterLD . Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology2019;18(5):428-38. ">Selim 2019</a> and <a href="./references#CD009280-bbs2-0002" title="YuY , ZhaoW . The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One2015;10(4):e0122371. ">Yu 2015</a> did not report on quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>risk in the control group</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ARDS:</b> acute respiratory distress syndrome; <b>CI:</b> confidence interval; <b>DFO:</b> deferoxamine; <b>IQR</b> : interquartile range; <b>mRS</b> : Modified Rankin Scale; <b>NIHSS: </b> National Institutes of Health Stroke Scale; <b>RCT</b> : randomised controlled trial; <b>RR</b> : risk ratio; <b>SAE</b> : serious adverse event; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels for imprecision because of low number of studies with small sample size. </p> <p><sup>b</sup>Downgraded by two levels for imprecision because of low number of studies with small sample size and non‐congruent follow‐up times. </p> <p><sup>c</sup>Downgraded by two levels for imprecision because of low number of studies with low sample size, non‐congruent follow‐up times and non uniformity in reporting. </p> <p><sup>d</sup>Time of measurement varied slightly between the control group (73 h, IQR 69 to 78) and the experimental group (74 h, IQR 69 to 78). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Iron chelator versus placebo for adults with acute stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009280.pub3/full#CD009280-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009280.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009280-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009280-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009280-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009280-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD009280-note-0012">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD009280-note-0009">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD009280-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD009280-note-0008">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD009280-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD009280-note-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009280-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009280-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009280\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009280\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009280\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009280\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009280\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=na56WA6j&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009280.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009280.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009280.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009280.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009280.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724245249"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009280.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724245253"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009280.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e5e1f5cabf409',t:'MTc0MDcyNDI0NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 